[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600912":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":33,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":33,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":33,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":33,"overallStatus":84,"whyStopped":33,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Mavacamten","EXPERIMENTAL","Add-on use of mavacamten on top of guideline-directed standard medical therapy",[13,14,15],"Drug: mavacamten","Drug: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol","Drug: diltiazem",{"label":17,"type":18,"description":19,"interventionNames":20},"No mavacamten","ACTIVE_COMPARATOR","Guideline-directed standard medical therapy group",[14,15],[22,29,34],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","mavacamten","Add Mavacamten to guideline-directed standard medical therapy for patients with hypertrophic cardiomyopathy (HCM) and mid-to-apical left ventricular obstruction.",[9],[28],"beta receptor blockers",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol","Administer an appropriate dose of beta-blockers according to the patient's tolerance.",[9,17],null,{"type":23,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"diltiazem","Administer an appropriate dose of diltiazem according to the patient's tolerance.",[9,17],[39],{"name":40,"role":41,"phone":42,"phoneExt":33,"email":43},"Xiaojie Xie, MD, PhD","CONTACT","571-87784700","xiexj@zju.edu.cn",[45],{"facility":46,"status":33,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Second Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310009","China","CN",{"type":53,"coordinates":54},"Point",[55,56],120.16142,30.29365,{"lat":56,"lon":55},[59],{"name":40,"role":41,"phone":42,"phoneExt":33,"email":43},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","xie xiaojie","MD, PhD","100600912","phase-4-the-therapeutic-value-of-mavacamten-in-hypertrophic-cardiomyopathy-with-mid-to-apical-left-ventricular-obstruction-100600912",false,"NCT07103655","The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction","The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction: A Prospective, Interventional, Real-World Clinical Study.","BRAVE-HCM","Inclusion Criteria:\n\n* Patients diagnosed with HCM according to the 2023 Chinese Guidelines for the Diagnosis and Treatment of Adult Hypertrophic Cardiomyopathy, meeting one of the following:\n\n  1. Left ventricular wall thickness ≥15 mm at end-diastole in any segment as assessed by echocardiography or cardiac magnetic resonance imaging (CMR);\n  2. Left ventricular wall thickness ≥13 mm in individuals with a confirmed pathogenic gene mutation or in genetically affected family members;\n  3. Exclusion of other cardiovascular, systemic, or metabolic disorders that may cause ventricular hypertrophy.\n\n     * Symptomatic non-outflow tract obstructive HCM patients (meeting criterion a and at least one of b or c):\n\n  \u003C!-- -->\n\n  1. Presence of clinical symptoms such as dyspnea, chest pain, dizziness, palpitations, or syncope, with New York Heart Association (NYHA) functional class II-III;\n  2. Maximal pressure gradient (PGmax) \\>30 mmHg in the mid-ventricle under resting or Valsalva maneuver as assessed by echocardiography;\n  3. PGmax \\>30 mmHg in the apical region under resting or Valsalva maneuver on echocardiography.\n\n     ③Ability to provide written informed consent (ICF) and any required privacy authorization prior to study enrollment.\n\n     Exclusion Criteria:\n\n     \\-\n* Obstructive hypertrophic cardiomyopathy (HCM), defined as a maximal left ventricular outflow tract pressure gradient (LVOT-PGmax) ≥30 mmHg at rest and during the Valsalva maneuver on echocardiography;\n\n  * Maximal right ventricular outflow tract pressure gradient (RVOT-PGmax) ≥16 mmHg at rest; ③ Left ventricular ejection fraction (LVEF) \\\u003C50% on echocardiography;\n\n    * Uncontrolled primary hypertension;\n\n      * Moderate or severe aortic valve stenosis and\u002For primary mitral valve disease with severe mitral regurgitation; ⑥ Known infiltrative or storage disorders mimicking the HCM phenotype (e.g., Fabry disease, cardiac amyloidosis); ⑦ Presence of severe infections, hepatic dysfunction, renal impairment, or other serious conditions significantly affecting life expectancy.","ALL","18 Years","75 Years",{"count":76,"type":77},132,"ESTIMATED","INTERVENTIONAL",[80],"PHASE4","This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic cardiomyopathy (HCM)-in patients with HCM characterized by mid-to-apical left ventricular obstruction.",[83],"Hypertrophic Cardiomyopathy (HCM)","NOT_YET_RECRUITING","2026-01-19",{"date":87,"type":88},"2026-01-21","ACTUAL",{"date":90,"type":77},"2026-01-01",{"date":92,"type":77},"2027-01-01",{"name":5,"class":6},1]